# Leisure-time physical activity and all-cause mortality and cardiovascular disease in adults with type 2 diabetes: Crosscountry comparison of cohort studies

Jakob Tarp <sup>1,\*</sup>, Mengyun Luo <sup>2,3</sup>, Miguel Adriano Sanchez-Lastra <sup>4,5,6</sup>, Knut Eirik Dalene <sup>7</sup>, Borja del Pozo Cruz <sup>8,9,10</sup>, Mathias Ried-Larsen <sup>11,12</sup>, Reimar Wernich Thomsen <sup>1</sup>, Ulf Ekelund <sup>4,7</sup>, Ding Ding <sup>2,3</sup>

<sup>1</sup> Department of Clinical Epidemiology, Aarhus University & Aarhus University Hospital, Aarhus 8200, Denmark

<sup>2</sup> Prevention Research Collaboration, Sydney School of Public Health, The University of Sydney, Camperdown 2006, NSW, Australia

<sup>3</sup> Charles Perkins Centre, the University of Sydney, Camperdown 2050, NSW, Australia

<sup>4</sup> Department of Sports Medicine, Norwegian School of Sports Sciences, Oslo 0806, Norway

<sup>5</sup> Department of Special Didactics, Faculty of Education and Sports Sciences, University of Vigo, Pontevedra 36005, Spain

<sup>6</sup> Well-Move Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo 36213, Spain

<sup>7</sup> Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo 0473, Norway

<sup>8</sup> Centre for Active and Healthy Ageing, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense 5230, Denmark

<sup>9</sup> Faculty of Education, University of C ádiz, C ádiz 11519, Spain

<sup>10</sup> Biomedical Research and Innovation Institute of C ádiz (INiBICA) Research Unit, Puerta del Mar University Hospital, University of C ádiz, C ádiz 11009, Spain

<sup>11</sup> The Centre of Inflammation and Metabolism & the Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark

<sup>12</sup> Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense 5230, Denmark

\* Corresponding author.

Email: jtarp@nih.no.

## **Supplementary File 1**

Supplementary Table 1. Comparison of self-reported variables in UK Biobank and China Kadoorie Biobank

Supplementary Table 2. Outcome censoring dates

Supplementary Table 3. Exclusion criteria

Supplementary Figure 1. Participant flowchart

Supplementary Table 4. UK Biobank expanded descriptive characteristics

Supplementary Table 5. China Kadoorie Biobank expanded descriptive characteristics

Supplementary Figure 2. Exposure distribution among cases and in all participants

Supplementary Table 6. Adjusted (standardized) 10-year cumulative all-cause mortality (%)

Supplementary Table 7. Sensitivity analyses, all-cause mortality

Supplementary Table 8. Descriptive characteristics by mode of transportation to work among adults

with type 2 diabetes in employment

Supplementary Table 9. Descriptive characteristics by occupational physical activity in adults with

type 2 diabetes in employment

Supplementary Table 10. Physical activity for transportation to work and all-cause mortality and cardiovascular disease among adults with type 2 diabetes in employment

Supplementary Table 11. Occupational physical activity and all-cause mortality and cardiovascular disease among adults with type 2 diabetes in employment

	UK Biobank	China Kadoorie Biobank
Data collection procedures	Self-administered questionnaire on a touch-screen and a verbal interview	Interviewer administered questionnaire
Physical activity		
Leisure-time physical activity	<ul> <li>Derived from questionnaire;</li> <li>Intensity: In the last 4 weeks did you spend any time doing the following; walking for pleasure/do strenuous sports/other exercises/light do-it-yourself/heavy do-it-yourself? <i>You can select more than one answer</i></li> <li>Frequency: How many times in the last 4 weeks did you go walking for pleasure/do strenuous sports/other exercises/light do-it-yourself/heavy do-it-yourself?</li> <li>Duration: Each time you went walking for pleasure/did strenuous sports/other exercises/light do-it-yourself, about how long did you spend doing it?</li> <li>Intensities were assigned as follows; walking (3.3 metabolic equivalents of task [METs]), light do-it-yourself (2.25 METs), heavy do-it-yourself (4.5 METs), strenuous sport (8.0 METs) and 'other exercise' (4.5 METs) (1).</li> </ul>	<ul> <li>Derived from questionnaire;</li> <li>Intensity: What is your <i>main</i> type of exercise; Tai Chi/Qigong, jogging/aerobic exercise, ball games, walking, swimming, other. Tick one box only.</li> <li>Frequency: During the past 12 months, how often did you do exercise in your leisure-time?</li> <li>Duration: About how many hours per week did you do such exercise in leisure time?</li> <li>Intensities were assigned as follows; Taichi/Qiqong/leisure walking (3.3 METs), jogging/aerobic exercise (7.4 METs), ball games (5.5 METs), brisk walking/gymnastics/folk dancing (4.2 METs), swimming (7.2 METs) (2), and 'other exercise' (4.5 METs) (1).</li> </ul>
	Combined to MET-hrs/week	Combined to MET-hrs/week
Transportation physical activity	Questionnaire; What types of transport do you use to get to and from work? (You can select more than one answer) - Car/motor vehicle - Walk - Public transport - Cycle	<ul> <li>During the past 12 months, how did you usually get to work?</li> <li>Mainly walk</li> <li>By motorbike</li> <li>By bicycle</li> <li>By bus/car/ferry/train</li> <li>Mainly stay at home or work near home</li> </ul>
	frequency of travels between home and work	Included as passive, walking, cycling, or working from home
Occupation	Questionnaire;	During past 12 months, how active were you at work?

Supplementary Table 1. Comparison of variables in UK Biobank and China Kadoorie Biobank

physical activity	Does your work involve walking or standing for most of the time? Does your work involve heavy manual or physical work? - Never/rarely - Sometimes - Usually - Always Included as sedentary work, some standing and no heavy work, heavy manual work, not in employment, or retired	<ul> <li>Mainly sedentary</li> <li>Standing occupation</li> <li>Manual work</li> <li>Heavy manual work</li> <li>Retired or housewife/husband or unemployed or disabled</li> <li>Included as sedentary work, standing, manual work, not in employment, or retired</li> </ul>
Sociodemographic		
Age	Attendance date minus birthdate, day of birth set to the 15 <sup>th</sup>	Attendance date minus birthdate
Education	Questionnaire;         Which of the following qualifications do you have? (You can select more than one)?         -       College or university degree         -       A levels/AS levels or equivalent         -       O levels/GCSEs or equivalent         -       CSEs or equivalent         -       NVQ or HND or HNC or equivalent         -       Other professional qualifications eg: nursing, teaching         Included as no qualifications, qualifications, not college/university degree	<ul> <li>What is the highest level of school education you ever received?</li> <li>No formal school</li> <li>Primary school</li> <li>Middle school</li> <li>High School</li> <li>Technical school / college</li> <li>University</li> </ul> Included as no school or primary school, middle school, or High school or higher
Income	na	What is the total income last year in your household? - <2500 yuan - 2500-4999 yuan - 5000-9999 yuan - 10,000-19,999 yuan - 20,000-34,999 yuan - ≥35,000 yuan Included as <10,000 yuan/y, 10,000-19,999 yuan/y, 20,000-34,999 yuan/y, or ≥35,000 yuan/y
Deprivation	Townsend deprivation index calculated from post-codes	na
Living with partner	Questionnaire; How are the other people who live with you related to you? (You can select more than one answer)	What is your current marital status? - Married - Widowed

	- Husband, wife or partner	- Separated / divorced
	- Son and/or daughter (include step-children)	- Never married
	- Brother and/or sister	
	- Mother and/or father)	
	- Grandparent	
	- Grandchild	
	- Other related	
	- Other unrelated	
		Included as married, yes/no
	Included as living with partner, yes/no	
	Questionnaire;	na
	What is your ethnic group?	
	- White	
	- Mixed	
Ethnicity	- Asian or Asian British	
	- Black or Black British	
	- Chinese	
	- Other ethnic group	
	Included as European, South Asian, African Caribbean, or other	
	na	Do you have any health care cover and the following items in your
		household?
Has health cover		- Health care cover
		Included as health cover, yes/no
Behavioral		
Dellavioral	Derived from questionnaire	Derived from questionnaire:
	Do you smoke tobacco now?	How often do you smoke tobacco now?
	- Yes on most or all days	- Do not smoke now
	- Only occasionally	- Only occasionally
	- No	- Yes on most days
Smoking	In the past, how often have you smoked tobacco?	- Yes, daily or almost every day
	- Smoked on most or all days	In the past, how frequently did you smoke?
	- Smoked occasionally	- Did not smoke
	- Just tried once or twice	- Smoked only occasionally
	- I have never smoked	- Smoked on most davs
		- Smoked daily or almost every day

	Included as never, former or current	Included as never, occasional, former regular, current
	Derived from questionnaire:	Derived from questionnaire:
	About how often do you drink alcohol?	During the past 12 months, how often did you drink any alcohol?
	- Daily or almost daily	- Never or almost never
	- Three or four times a week	- Only occasionally
	- Once or twice a week	- Only at certain seasons
	- One to three times a month	- Every month but less than weekly
	- Special occasions only	- Usually at least once a week
		In the past, did you ever have a period of at least 1 year during which
	Did you previously drink alcohol?	you usually drank some alcohol at least once a week?
Alcohol intako		
		During the past 12 months, on how many days did you drink alcohol in
		a typical week?
		= 1-2 days/wook
		-3.5 days/week
		- Daily or almost every day
		- Daily of almost every day
		Included as never/occasionally former weekly current <3 days/week
	Included as never, former, current (<3 times/week), or current (>3	current >3 days/week
	times/week)	current =0 days/week
	Derived from questionnaire:	During the past 12 months, about how often did you eat the following
	How often do you eat processed meats (such as bacon, ham	foods?
	sausages meat pies kebabs burgers chicken nuggets)?	Meat
	How often do you eat beef? (Do not count processed meats)	- Daily
	How often do you eat lamb/mutton? (Do not count processed meats)	- 4-6 days per week
	How often do you eat pork? (Do not count processed meats such as	- 1-3 days per week
	bacon or ham)	- Monthly
	How often do you eat oily fish? (e.g. sardines, salmon, mackerel	- Never/rarely
Dietary quality	herring)	Fresh fruit
	How often do you eat other types of fish? (e.g. cod, tinned tuna	- Daily
	haddock)	- 4-6 days per week
	- Never	- 1-3 days per week
	- Less than once a week	- Monthly
	- Once a week	- Never/rarely
	- 2-4 times a week	
	- 5-6 times a week	

	- Once or more daily	
	On average how many heaped tablespoons of COOKED vegetables would you eat per DAY? (Do not include potatoes; put '0' if you do not eat any) On average how many heaped tablespoons of SALAD or RAW vegetables would you eat per DAY? (Include lettuce, tomato in sandwiches; put '0' if you do not eat any) About how many pieces of FRESH fruit would you eat per DAY? (Count one apple, one banana, 10 grapes etc as one piece; put '0' if you do not eat any) About how many pieces of DRIED fruit would you eat per DAY? (Count one prune, one dried apricot, 10 raisins as one piece; put '0' if you do not eat any) - Free text answer	
	Included as dietary quality index based on minimum 400 grams of fruit or vegetable/day, $\leq 3$ servings of red meat + $\leq 1$ serving of processed meat/week, and $\geq 2$ servings of fish including 1 with oily fish/week. Meeting 0, 1 or 2-3 targets.	Included as fruit consumption ≥4 days/week, yes/no and meat consumption ≥4 days/week, yes/no
Health-related		
Family history of type 2 diabetes, CVD, or cancer	Questionnaire; Has/did your father ever suffer from? (You can select more than one answer)Has/did your mother ever suffer from? (You can select more than one answer)Have any of your brothers or sisters suffered from any of the following diseases? (You can select more than one answer)Has/did your ADOPTED father ever suffer from? (You can select more than one answer)Has/did your ADOPTED mother ever suffer from? (You can select more than one answer)Has/did your ADOPTED mother ever suffer from? (You can select more than one answer)Have any of your ADOPTED brothers or sisters suffered from any of the following diseases? (You can select more than one answer)-Prostate cancer Severe depression Parkinson's disease	Did any of your parents, siblings or children have the following diseases? - Stroke - Heart attack - Diabetes - Mental disorder - Cancer

	- Alzheimer's disease/dementia	
	- Diabetes	
	- High blood pressure	
	- Chronic bronchitis/emphysema	
	- Breast cancer	
	- Bowel cancer	
	Stroko	
	- Sticke Hoart disease	Included as family history of diabates, cardiovascular disease, or
		cancer, yes/no
	Included as family history of diabetes, cardiovascular disease, or	
	cancer, yes/no	
	Derived from questionnaire and verbal interview;	Derived from questionnaire;
	Has a doctor ever told you that you have diabetes?	Has a doctor ever told you that you had had the following disease?
	- Yes	- Diabetes
	- No	Age at first diagnosis?
	Did you only have diabetes during pregnancy?	- Free text answer
	- Yes	Still on treatment?
	- No	- Free text answer
	- Not applicable	
	What was your age when the diabetes was first diagnosed?	
	- Free text answer	
	Did you start insulin within one year of your diagnosis of diabetes?	
	- Free text answer	
	Do you regularly take any of the following medications? (You can	
Inclusion method	select more than one answer)	
	- Cholesterol lowering medication	
	- Blood pressure medication	
	- Insulin	
	- Hormone replacement therapy	
	- Oral contraceptive pill or mini pill	
	- None of the above	
	What is your ethnic group?	
	- White	
	- Mixed	
	- Asian or Asian British	
	- Black or Black British	
	- Chinese	

	- Other ethnic group	
	Combined with measured Hba1c and included as inclusion from self- reported type 2 diabetes/use of diabetes medication or from biochemistry	Combined with measured random glucose and included as inclusion from self-reported type 2 diabetes or from biochemistry
Experienced food shortage with weight-loss	na	Derived from questionnaire; Have you ever experienced any severe food shortage? - Yes - No During the most severe food shortage you experienced: did you lose weight? - Yes - No Included as experienced food shortage with weight loss, yes/no
Depression	Verbal interview;	Composite International Diagnostic Interview
Loneliness	Questionnaire; Do you often feel lonely? Included as ves/no	na
Diabetes duration	Calculated as attendance date minus age at diabetes diagnosis	Calculated as attendance date minus age at diabetes diagnosis
Use of medication	Derived from verbal interview; Type and number of prescription medications taken. Included as; use of statins, yes/no use of blood-pressure lowering drugs, 0, 1, 2, or ≥3 Use of glucose-lowering drugs, none, insulin only, oral only, or oral + insulin	For CHD, stroke, hypertension and diabetes what is the current medication? - Aspirin - ACE-I - Beta-blocker - Statins - Diuretics - Ca <sup>++</sup> antagonist - Chlorpropamide or metformin - Insulin Included as; use of statins, yes/no use of blood-pressure lowering drugs, 0, 1 or ≥2 use of glucose-lowering drugs, none, insulin only, oral only, or oral + insulin

Na: not applicable

	Supplementary	/ Table 2.	Outcome	censoring	dates
--	---------------	------------	---------	-----------	-------

	All-cause mortality	Cardiovascular mortality	Major adverse cardiovascular events
UK Biobank			
England	30 September 2021	30 September 2021	30 September 2021
Wales	30 September 2021	30 September 2021	31 March 2016
Scotland	31 October 2021	31 October 2021	31 July 2021
China Kadoorie Biobank	31 December 2016	31 December 2016	31 December 2016

	Conditions	Data source
UK Biobank		
Cardiovascular disease	Myocardial infarction, stroke, ischaemic stroke, subarachnoid haemorrhage, brain haemorrhage	Algorithmically defined outcomes (Field IDs: 42000, 42006, 42008, 42010, 42012)
	Angina, heart failure	Hospital In-patient data (Field IDs: 41270, 41280, 41271, 41281)
Cancer	Any cancer, excluding non-melanoma skin cancer	Touch-screen questionnaire (Field ID: 2453) Verbal interview (Field ID: 20001) Cancer registry (Field ID: 40006)
COPD		Algorithmically defined outcomes (Field ID: 42016)
Other chronic respiratory diseases	Bronchiectasis, interstitial lung disease, asbestosis, pulmonary fibrosis, fibrosing alveolitis/unspecified alveolitis, respiratory failure	Verbal interview (Field ID: 20002)
Chronic	Rheumatoid arthritis, vasculitis, giant cell/temporal arteritis,	Verbal interview (Field ID: 20002)
immunological/systemic	polymyalgia rheumatica, Wegners granulmatosis, microscopic polyarteritis, polyarteritis nodosa, systemic lupus	
diseases	erythematosis/sle, sjogren's syndrome/sicca syndrome, dermatopolymyositis, dermatomyositis, polymyositis, scleroderma/systemic sclerosis, chronic fatigue syndrome, antiphospholipid syndrome	
Liver failure/cirrhosis	Liver failure/cirrhosis, primary biliary cirrhosis, alcoholic liver disease / alcoholic cirrhosis	Verbal interview (Field ID: 20002)
Renal failure	Renal/kidney failure, renal failure requiring dialysis, renal failure not requiring dialysis, kidney nephropathy, iga nephropathy, diabetic nephropathy, nephritis, glomerulnephritis	Verbal interview (Field ID: 20002)
Psychological/psychiatric problems	Schizophrenia, mania/bipolar disorder/manic depression, deliberate self-harm/suicide attempt, post-traumatic stress disorder	Verbal interview (Field ID: 20002)
Substance	Alcohol dependency, opioid dependency, other substance	Verbal interview (Field ID: 20002)
abuse/dependency	abuse/dependency	
Anorexia/bulimia/other eating disorder	Anorexia/bulimia/other eating disorder	Verbal interview (Field ID: 20002)
Chronic/degenerative neurological problem	Chronic/degenerative neurological problem, Parkinson's disease, dementia/Alzheimer's/cognitive impairment, motor neuron disease, myasthenia gravis, multiple sclerosis, other	Verbal interview (Field ID: 20002)

	demyelinating disease (not multiple sclerosis)	
Chronic widespread pain		Touch-screen questionnaire (Field ID: 2956)
Unable to walk		Touch-screen questionnaire (Field ID: 864)
Living in care home		Touch-screen questionnaire (Field ID: 670)
Mobility allowance/receiving		Touch-screen questionnaire (Field ID: 6146)
disability allowance/blue		
badge		
Underweight	Body mass index< 18.5	Height and weight measured by trained staff (Field ID: 21001)
China Kadoorie Biobank		
Cardiovascular disease	Coronary heart disease, stroke, transient ischaemic attack,	Interviewer-assisted questionnaire
Rheumatic heart disease		Interviewer-assisted questionnaire
Cancer		Interviewer-assisted questionnaire
Chronic respiratory diseases	Emphysema/bronchitis	Interviewer-assisted questionnaire
Tuberculosis, still on		Interviewer-assisted questionnaire
treatment		
Cirrhosis/chronic hepatitis,		Interviewer-assisted questionnaire
still on treatment		
Kidney disease, still on		Interviewer-assisted questionnaire
treatment		
Rheumatic arthritis, still on		Interviewer-assisted questionnaire
treatment		
Psychiatric disorders, still on		Interviewer-assisted questionnaire
treatment		
Neurasthenia, still on		Interviewer-assisted questionnaire

treatment		
Generalized anxiety disorder		Composite International Diagnostic Interview (CIDI) B
Continuous pain/discomfort		Interviewer-assisted questionnaire
Underweight	Body mass index< 18.5	Height and weight measured by trained staff

### Supplementary Figure 1. Participant flowchart



<sup>1</sup>Prevalent type 2 diabetes defined by algorithm by Eastwood et al. 2016 or from measured Hba1c ≥48 mmol/mol in UK Biobank and from self-reported current diabetes with a diagnosis age above 30 years, a random plasma blood glucose ≥11.1 mmol/L, or fasting plasma blood glucose ≥7.0 mmol/L in China Kadoorie Biobank.

<sup>2</sup>Observations, not unique participants

<sup>3</sup>Implasible values defined as sum of self-reported behaviors >24 hours/day. In China Kadoorie Biobank, 7006 participants were excluded because they completed a separate physical activity questionnaire (section for rural farmers).

Supplementary Table 4. UK Biobank	expanded descriptive characteristics
-----------------------------------	--------------------------------------

		Leisure-time	Leisure-time	Leisure-time
	No leisure-time	physical activity	physical activity	physical activity
	physical activity	below	at	above
		recommendation	recommendation	recommendation
UK Biobank				
N (% Women)	1391 (47.0)	5775 (41.2)	2956 (37.3)	4791 (29.2)
Age (years), mean (SD)	58.2 (7.3)	59.1 (7.3)	59.7 (7.2)	60.3 (7.1)
Body mass index (kg/m^2), mean (SD)	33.3 (6.6)	31.6 (5.7)	30.6 (5.3)	29.9 (5.0)
LTPA (MET-hours/wk), mean (SD)	0.0 (0.0)	3.2 (2.1)	10.8 (2.1)	36.8 (26.7)
Participation in sports (yes), No. (%)	0 (0.0)	36 (0.6)	93 (3.1)	594 (12.4)
Duration of diabetes (years), mean (SD)	5.4 (7.2)	5.1 (6.6)	5.1 (6.7)	5.4 (7.1)
Education, No. (%)				
No qualifications	392 (28.2)	1278 (22.1)	542 (18.3)	901 (18.8)
Other qualifications than college/university degree	691 (49.7)	2986 (51.7)	1471 (49.8)	2418 (50.5)
College/University degree	308 (22.1)	1511 (26.2)	943 (31.9)	1472 (30.7)
Townsend Index, mean (SD)	0.4 (3.5)	-0.7 (3.3)	-1.1 (3.1)	-1.4 (3.0)
living with partner (yes), No. (%)	859 (61.8)	3988 (69.1)	2120 (71.7)	3575 (74.6)
Ethnicity, No. (%)				
European	1115 (80.2)	5028 (87.1)	2653 (89.7)	4400 (91.8)
South Asian	98 (7.0)	305 (5.3)	132 (4.5)	153 (3.2)
African Caribbean	98 (7.0)	216 (3.7)	82 (2.8)	103 (2.1)
Other	80 (5.8)	226 (3.9)	89 (3.0)	135 (2.8)
Occupational Physical activity, No. (%)				
Sedentary	272 (19.6)	1058 (18.3)	483 (16.3)	566 (11.8)
Some standing, No heavy	223 (16.0)	1032 (17.9)	496 (16.8)	645 (13.5)
Heavy manual work	352 (25.3)	1170 (20.3)	506 (17.1)	790 (16.5)
Not in employment	157 (11.3)	463 (8.0)	205 (6.9)	294 (6.1)
Retired	387 (27.8)	2052 (35.5)	1266 (42.8)	2496 (52.1)
Transportation, No. (%)				
Passive	650 (46.7)	2575 (44.6)	1127 (38.1)	1465 (30.6)
Walking	119 (8.6)	361 (6.3)	172 (5.8)	214 (4.5)
Cycling	7 (0.5)	67 (1.2)	51 (1.7)	123 (2.6)
Working from home	71 (5.1)	257 (4.5)	135 (4.6)	199 (4.2)
Not in employment/retired	544 (39.1)	2515 (43.5)	1471 (49.8)	2790 (58.2)

Smoking, No. (%)				
Never	685 (49.2)	2885 (50.0)	1498 (50.7)	2255 (47.1)
Former	514 (37.0)	2273 (39.4)	1203 (40.7)	2120 (44.2)
Current	192 (13.8)	617 (10.7)	255 (8.6)	416 (8.7)
Alcohol intake, No. (%)				
Never	165 (11.9)	454 (7.9)	175 (5.9)	252 (5.3)
Former	105 (7.5)	275 (4.8)	145 (4.9)	222 (4.6)
Current,<3 times/week	812 (58.4)	3249 (56.3)	1577 (53.3)	2365 (49.4)
Current, ≥3 times/week	309 (22.2)	1797 (31.1)	1059 (35.8)	1952 (40.7)
Diet quality index, No. (%)				
0 (lowest diet quality)	382 (27.5)	1279 (22.2)	569 (19.3)	871 (18.2)
1	617 (44.4)	2405 (41.7)	1151 (38.9)	1745 (36.4)
2-3 (highest diet quality)	392 (28.2)	2091 (36.2)	1236 (41.8)	2175 (45.4)
Body mass index categories (kg/m^2), No. (%)				
18.5-25	107 (7.7)	589 (10.2)	373 (12.6)	701 (14.6)
25-30	365 (26.2)	1936 (33.5)	1080 (36.5)	1989 (41.5)
30-35	428 (30.8)	1861 (32.2)	953 (32.2)	1415 (29.5)
≥35	491 (35.3)	1389 (24.1)	550 (18.6)	686 (14.3)
Family history of CVD, cancer or diabetes (yes), No. (%)	1194 (85.8)	4910 (85.0)	2520 (85.3)	4069 (84.9)
Depression (yes), No. (%)	103 (7.4)	311 (5.4)	118 (4.0)	203 (4.2)
Loneliness (yes), No. (%)	411 (29.5)	1223 (21.2)	521 (17.6)	797 (16.6)
Beta-blockers (yes), No. (%)	197 (14.2)	728 (12.6)	326 (11.0)	537 (11.2)
Calcium-channel blockers (yes), No. (%)	319 (22.9)	1139 (19.7)	554 (18.7)	923 (19.3)
Renin-angiotensin-system antagonists (yes), No. (%)	701 (50.4)	2775 (48.1)	1436 (48.6)	2196 (45.8)
Thiazide diuretics (yes), No. (%)	278 (20.0)	978 (16.9)	525 (17.8)	701 (14.6)
Loop diuretics (yes), No. (%)	47 (3.4)	134 (2.3)	52 (1.8)	75 (1.6)
Potassium-sparring diuretics (yes), No. (%)	7 (0.5)	33 (0.6)	16 (0.5)	20 (0.4)
Statins (yes), No. (%)	881 (63.3)	3649 (63.2)	1934 (65.4)	3067 (64.0)
Hba1c (mmol/mol), mean (SD)*	55.8 (14.3)	54.7 (14.3)	53.1 (13.7)	52.9 (13.9)
Doctor diagnosis or on treatment for type 2 diabetes (yes),	1101 (79.2)	4578 (79.3)	2405 (81.4)	3921 (81.8)
No. (%)**				
Insulin medication (yes), No. (%)***	148 (13.4)	559 (12.2)	274 (11.4)	469 (12.0)
Metformin medication (yes), No. (%)***	723 (65.7)	2910 (63.6)	1376 (57.2)	2219 (56.6)
Other glucose-lowering medication (yes), No. (%)***	347 (31.5)	1273 (27.8)	625 (26.0)	1001 (25.5)
Any non-insulin glucose-lowering drug (yes), No. (%)***	778 (70.7)	3125 (68.3)	1489 (61.9)	2401 (61.2)

Categories of leisure-time physical activity defined as; none (0 MET-hrs/week), below recommendation (>0 to 7.49 MET-hrs/week), at recommendation (7.5-14.9 MET-hrs/week), and above recommendation (≥15 MET-hrs/week).

\*n=14,078

\*\*Individuals with type 2 diabetes identified from self-report or use of glucose-lowering drugs (Eastwood et al., 2016)

\*\*\*Reported use at nurse interview, individuals identified with type 2 diabetes solely from measured Hba1c are not included in the percentage denominator. MET: metabolic equivalent, CVD: cardiovascular disease, ACE: angiotensin-converting enzyme

		Leisure-time	Leisure-time	Leisure-time
	No leisure-time	physical activity	physical activity	physical activity
	physical activity	below	at	above
		recommendation	recommendation	recommendation
China Kadoorie Biobank				
% Women	9523 (61.7)	616 (53.4)	1186 (54.3)	6132 (60.3)
Age (years), mean (SD)	55.4 (9.7)	56.8 (9.6)	58.7 (9.4)	61.2 (8.4)
Body mass index (kg/m^2), mean (SD)	25.5 (3.5)	25.5 (3.3)	25.3 (3.2)	25.3 (3.2)
LTPA (MET-hours/wk), mean (SD)	0.0 (0.0)	5.3 (1.6)	11.7 (1.8)	35.9 (19.2)
Participation in heavy physical activity/exercise, No. (%)*	1002 (10.5)	53 (8.6)	147 (12.4)	803 (13.1)
Duration of diabetes (years), mean (SD)	2.6 (4.2)	3.5 (4.9)	3.5 (4.7)	4.2 (5.3)
Education, No. (%)				
No school or primary school	4831 (50.7)	230 (37.3)	449 (37.9)	2327 (37.9)
Middle school	2609 (27.4)	201 (32.6)	366 (30.9)	1849 (30.2)
High school or higher	2083 (21.9)	185 (30.0)	371 (31.3)	1956 (31.9)
Household income, No. (%)				
<10,000 yuan/year	1660 (17.4)	88 (14.3)	185 (15.6)	815 (13.3)
10,000-19,999 yuan/year	2651 (27.8)	215 (34.9)	376 (31.7)	2098 (34.2)
20,000-34,999 yuan/year	2838 (29.8)	172 (27.9)	329 (27.7)	1851 (30.2)
≥35,000 yuan/year	2374 (24.9)	141 (22.9)	296 (25.0)	1368 (22.3)
Marital Status (Married), No. (%)	8392 (88.1)	527 (85.6)	1024 (86.3)	5235 (85.4)
Health cover (yes), No. (%)	8157 (85.7)	522 (84.7)	982 (82.8)	5170 (84.3)
Occupational Physical activity, No. (%)				
Sedentary	1691 (17.8)	125 (20.3)	180 (15.2)	492 (8.0)
Standing	907 (9.5)	57 (9.3)	67 (5.6)	174 (2.8)
Manual work	1439 (15.1)	56 (9.1)	94 (7.9)	169 (2.8)
Not in employment	2784 (29.2)	122 (19.8)	235 (19.8)	979 (16.0)
Retired	2702 (28.4)	256 (41.6)	610 (51.4)	4318 (70.4)
Transportation, No. (%)				
Passive	1712 (18.0)	109 (17.7)	133 (11.2)	360 (5.9)
Walking	693 (7.3)	44 (7.1)	80 (6.7)	199 (3.2)
Cycling	794 (8.3)	46 (7.5)	70 (5.9)	124 (2.0)
Working from home	838 (8.8)	39 (6.3)	58 (4.9)	152 (2.5)
Not in employment/retired	5486 (57.6)	378 (61.4)	845 (71.2)	5297 (86.4)

Supplementary Table 5. China Kadoorie Biobank expanded descriptive characteristics

Smoking, No. (%)				
Never	6179 (64.9)	338 (54.9)	707 (59.6)	4078 (66.5)
Occasional	431 (4.5)	37 (6.0)	75 (6.3)	341 (5.6)
Former	637 (6.7)	64 (10.4)	129 (10.9)	696 (11.4)
Current	2276 (23.9)	177 (28.7)	275 (23.2)	1017 (16.6)
Alcohol intake, No. (%)	, <i>, , , , , , , , , , , , , , , ,</i>			
Never/rarely	7336 (77.0)	438 (71.1)	886 (74.7)	4912 (80.1)
Former weekly	352 (3.7)	31 (5.0)	73 (6.2)	354 (5.8)
Current, <3 times/week	647 (6.8)	69 (11.2)	91 (7.7)	341 (5.6)
Current, ≥3 times/week	1188 (12.5)	78 (12.7)	136 (11.5)	525 (8.6)
Regular fruit consumption (≥4 days/week), No. (%)	2582 (27.1)	234 (38.0)	454 (38.3)	2916 (47.6)
Regular meat consumption (≥4 days/week), No. (%)	5385 (56.5)	394 (64.0)	780 (65.8)	4291 (70.0)
Body mass index categories (kg/m^2), No. (%)				
18.5-25	4446 (46.7)	281 (45.6)	594 (50.1)	2987 (48.7)
25-30	4120 (43.3)	282 (45.8)	491 (41.4)	2673 (43.6)
30-35	853 (9.0)	50 (8.1)	93 (7.8)	430 (7.0)
≥35	104 (1.1)	3 (0.5)	8 (0.7)	42 (0.7)
Family history of CVD, cancer or diabetes (yes), No. (%)	4524 (47.5)	319 (51.8)	617 (52.0)	2952 (48.1)
Experienced food shortage with weight loss (yes), No. (%)	851 (8.9)	32 (5.2)	81 (6.8)	376 (6.1)
Major depression in last 12 months (yes), No. (%)	50 (0.5)	2 (0.3)	5 (0.4)	11 (0.2)
Beta-blockers (yes), No. (%)	240 (2.5)	15 (2.4)	26 (2.2)	222 (3.6)
ACE-inhibitors (yes), No. (%)	232 (2.4)	16 (2.6)	31 (2.6)	231 (3.8)
Diuretics (yes), No. (%)	76 (0.8)	3 (0.5)	6 (0.5)	49 (0.8)
Calcium-antagonists (yes), No. (%)	427 (4.5)	44 (7.1)	80 (6.7)	501 (8.2)
Statins (yes), No. (%)	44 (0.5)	2 (0.3)	6 (0.5)	20 (0.3)
Random blood glucose (mmol/L), mean (SD)**	12.2 (5.5)	12.3 (5.6)	12.0 (5.5)	11.5 (5.3)
Doctor diagnosis of type 2 diabetes (yes), No. (%)***	4379 (46.0)	337 (54.7)	701 (59.1)	3810 (62.1)
Insulin medication (yes), No. (%)****	460 (10.5)	52 (15.4)	83 (11.8)	503 (13.2)
Chlorpropamide or metformin medication (yes), No. (%)****	2382 (54.4)	177 (52.5)	386 (55.1)	2094 (55.0)

Categories of leisure-time physical activity defined as; none (0 MET-hrs/week), below recommendation (>0 to 7.49 MET-hrs/week), at recommendation (7.5-14.9 MET-hrs/week), and above recommendation (≥15 MET-hrs/week).

\*Includes work, transportation, domestic and leisure activities

\*\*n=17,402

\*\*\*Self-reported diagnosis of diabetes from a doctor \*\*\*\*The denominator in the percentage is individuals with a doctor diagnosis of T2D.

MET: metabolic equivalent, CVD: cardiovascular disease, ACE: angiotensin-converting enzyme

Supplementary Figure 2. Exposure distribution among cases and in all participants



**All-cause Mortality** 



	No leisure-time physical activity	Leisure-time physical activity below recommendation	Leisure-time physical activity at recommendation	Leisure-time physical activity above recommendation	
All-Cause Mortality					
UK Biobank					
Adjusted 10-year cumulative mortality (%)	6.1 (5.7, 6.5)	5.9 (5.2, 6.6)	5.6 (4.8, 6.7)	5.5 (4.8, 6.3)	
Adjusted difference in 10-year cumulative mortality	reference	-0.2 (-0.8, 0.4)	-0.4 (-1.3, 0.4)	-0.6 (-1.3, 0.0)	
China Kadoorie Biobank					
Adjusted 10-year cumulative mortality (%)	13.2 (12.7, 13.7)	11.8 (9.6, 14.4)	11.9 (10.4, 13.7)	11.6 (10.9, 12.3)	
Adjusted difference in 10-year cumulative mortality	reference	-1.4 (-3.8, 0.9)	-1.3 (-2.9, 0.3)	-1.6 (-2.3, -1.0)	

#### Supplementary Table 6. Adjusted (standardized) 10-year cumulative all-cause mortality (%)

Categories of leisure-time physical activity defined as; none (0 MET-hrs/week), below recommendation (>0 to 7.49 MET-hrs/week), at recommendation (7.5-14.9 MET-hrs/week), and above recommendation (≥15 MET-hrs/week).

Based on model 3. Estimates were obtained from a flexible parametric survival model using restricted cubic spline functions with three knots (25th, 50th and 75th of the uncensored log survival times) to model the baseline cumulative hazard.

### Supplementary Table 7. Sensitivity analyses, all-cause mortality

	No leisure-time physical activity	Leisure-time physical activity below recommendation	Leisure-time physical activity at recommendation	Leisure-time physical activity above recommendation
UK Biobank				
Main analysis, N = 14,913, deaths = 1571				
HR (95%CI)	1 [reference]	0.94 (0.79, 1.12)	0.90 (0.74, 1.10)	0.85 (0.70, 1.02)
Excluding ever smokers, N = 7323, deaths = 583	685 / 64	2885 / 216	1498 / 121	2255 / 182
HR (95%CI)	1 [reference]	0.87 (0.65, 1.15)	0.92 (0.67, 1.25)	0.85 (0.63, 1.15)
Excluding individuals classified as 'possible type 2 diabetes'	1360 / 156	5679 / 596	2908 / 299	4689/ 482
and Hba1c <48 mmol/mol, $N = 13,681$ , deaths = 1393				
HR (95%CI)	1 [reference]	0.95 (0.80, 1.14)	0.91 (0.75, 1.12)	0.86 (0.71, 1.05)
24hr dietary recall sample, N = 5780, deaths = 410	441 / 29	2116 / 150	1192 / 86	2031 / 145
No adjustment for 24hr dietary recall (HR [95%CI])	1 [reference]	1.12 (0.75, 1.67)	1.19 (0.77, 1.84)	1.06 (0.70, 1.60)
Adjustment for 24hr dietary recalls* (HR [95%CI])	1 [reference]	1.12 (0.75, 1.68)	1.19 (0.77, 1.84)	1.06 (0.70, 1.61)
China Kadoorie Biobank				
Main analysis, N = 17,457, deaths = 2357				
HR (95%CI)	1 [reference]	0.87 (0.68, 1.10)	0.88 (0.74, 1.03)	0.77 (0.70, 0.85)
Excluding ever smokers, N = 11,302, deaths = 1406	6179 / 783	338 / 38	707 / 88	4078 / 497
HR (95%CI)	1 [reference]	0.89 (0.64, 1.23)	0.84 (0.67, 1.05)	0.77 (0.68, 0.88)

Categories of leisure-time physical activity defined as; none (0 MET-hrs/week), below recommendation (>0 to 7.49 MET-hrs/week), at recommendation (7.5-14.9 MET-hrs/week), and above recommendation (≥15 MET-hrs/week).

Based on model 3. MET: metabolic equivalent, CVD: cardiovascular disease

\*Adjustment for total energy intake, dietary intake of fibers, and the ratio of polyunsaturated to saturated fat. Follow-up was started 3 years after the last completed dietary recall.

\*\*As model 3 + adjusted for prevalent CVD and prevalent cancer

	Passive transportation	Walking	Cycling
LIK Bishank			
	E917 (22 2)	966 (44.0)	249(465)
N (% WOMEN)	5817 (32.2)		248 (10.5)
Age (years), mean (SD)	55.8 (6.7)		53.6 (7.0)
Body mass index (kg/m <sup>2</sup> ), mean (SD)	31.6 (5.8)	30.8 (5.9)	29.2 (5.0)
LIPA (MET-hours/wk), mean (SD)	12.3 (18.9)	11.8 (17.4)	20.6 (22.7)
Participation in sports, No. (%)	346 (5.9)	48 (5.5)	29 (11.7)
Duration of diabetes (years), mean (SD)	4.5 (6.3)	3.8 (5.1)	3.8 (5.7)
Education, No. (%)			
No qualifications	775 (13.3)	107 (12.4)	29 (11.7)
Other qualifications than college/university degree	3284 (56.5)	432 (49.9)	102 (41.1)
College/University degree	1758 (30.2)	327 (37.8)	117 (47.2)
Townsend Index, mean (SD)	-0.9 (3.2)	0.0 (3.4)	-0.8 (3.1)
Smoking, No. (%)			
Never	2927 (50.3)	495 (57.2)	114 (46.0)
Former	2237 (38.5)	292 (33.7)	106 (42.7)
Current	653 (11.2)	79 (9.1)	28 (11.3)
Family history of CVD, cancer or diabetes (yes), No. (%)	4917 (84.5)	741 (85.6)	198 (79.8)
Statins (yes), No. (%)	3457 (59.4)	500 (57.7)	139 (56.0)
Use of blood-pressure lowering drugs, No (%)	, <i>,</i> , , , , , , , , , , , , , , , , ,	\$ 7	, <i>,</i> , ,
0	3711 (63.8)	574 (66.3)	183 (73.8)
1	1243 (21.4)	177 (20.4)	40 (16.1)
2	681 (11.7)	88 (10.2)	19 (7.7)
3 or more	182 (3.1)	27 (3.1)	6 (2.4)
Doctor diagnosis or on treatment for type 2 diabetes (yes), No. (%)*	4488 (77.2)	641 (74.0)	170 (68.5)
Use of blood-glucose lowering drugs, No (%)**			, <i>, , , , , , , , , , , , , , , , , , </i>
None	1301 (29.0)	198 (30.9)	54 (31.8)
Insulin only	208 (4.6)	28 (4.4)	10 (5.9)
Non-insulin only	2651 (59.1)	378 (59.0)	95 (55.9)
Insulin and non-insulin	328 (7.3)	37 (5.8)	11 (6.5)
	, í		, í
China Kadoorie Biobank			
% Women	2229 (25.6)	990 (42.0)	1000 (38.7)
Age (years), mean (SD)	48.1 (6.7)	49.7 (7.0)	50.3 (6.9)

Supplementary Table 8. Descriptive characteristics by mode of transportation to work among adults with type 2 diabetes in employment

Body mass index (kg/m^2), mean (SD)	25.8 (3.3)	25.5 (3.2)	24.8 (3.2)
LTPA (MET-hours/wk), mean (SD)	5.9 (13.9)	7.4 (14.8)	4.9 (12.1)
Participation in heavy physical activity/exercise, No. (%)***	259 (11.6)	107 (10.8)	127 (12.7)
Duration of diabetes (years), mean (SD)	1.9 (3.2)	2.2 (3.5)	1.8 (3.4)
Education, No. (%)		, , ,	, ,
No school or primary school	425 (19.1)	201 (20.3)	376 (37.6)
Middle school	808 (36.2)	319 (32.2)	325 (32.5)
High school or higher	996 (44.7)	470 (47.5)	299 (29.9)
Smoking, No. (%)			
Never	766 (34.4)	508 (51.3)	476 (47.6)
Occasional	185 (8.3)	56 (5.7)	82 (8.2)
Former	219 (9.8)	93 (9.4)	94 (9.4)
Current	1059 (47.5)	333 (33.6)	348 (34.8)
Family history of CVD, cancer or diabetes (yes), No. (%)	1265 (56.8)	569 (57.5)	518 (51.8)
Statins (yes), No. (%)	6 (0.3)	2 (0.2)	2 (0.2)
Use of blood-pressure lowering drugs, No (%)			
0	2077 (93.2)	907 (91.6)	943 (94.3)
1	128 (5.7)	74 (7.5)	49 (4.9)
2 or more	24 (1.1)	9 (0.9)	8 (0.8)
Doctor diagnosis or on treatment for type 2 diabetes (yes), No. (%)*	942 (42.3)	448 (45.3)	384 (38.4)
Use of blood-glucose lowering drugs, No (%)**			
None	364 (38.6)	179 (40.0)	155 (40.4)
Insulin only	95 (10.1)	77 (17.2)	24 (6.3)
Chlorpropamide or metformin only	466 (49.5)	187 (41.7)	204 (53.1)
Insulin and Chlorpropamide or metformin	17 (1.8)	5 (1.1)	1 (0.3)

LTPA: leisure-time physical activity, MET: metabolic equivalent, CVD: cardiovascular disease

\*Individuals with type 2 diabetes identified from self-report or use of glucose-lowering drugs Eastwood et al., 2016, UKB Biobank) or from self-reported diagnosis of diabetes from a doctor (China Kadoorie Biobank).

\*\*Individuals identified with type 2 diabetes solely from measured Hba1c (UK Biobank) or random blood glucose (China Kadoorie Biobank) are not included in the denominator.

\*\*\*Includes work, transportation, domestic and leisure activities

	, ,		
	Sedentary	Standing/walking	Manual work*
UK Biobank			
N (% Women)	2379 (34.3)	2396 (34.4)	2818 (28.9)
Age (years), mean (SD)	55.3 (6.8)	56.5 (6.7)	55.7 (6.7)
Body mass index (kg/m^2), mean (SD)	31.7 (6.2)	31.3 (5.7)	31.3 (5.4)
LTPA (MET-hours/wk), mean (SD)	10.7 (14.2)	12.2 (16.3)	14.8 (24.4)
Participation in sports, No. (%)	168 (7.1)	162 (6.8)	133 (4.7)
Duration of diabetes (years), mean (SD)	4.4 (6.0)	4.5 (6.2)	4.5 (6.4)
Education, No. (%)			
No qualifications	124 (5.2)	215 (9.0)	644 (22.9)
Other qualifications than college/university degree	1247 (52.4)	1215 (50.7)	1685 (59.8)
College/University degree	1008 (42.4)	966 (40.3)	489 (17.4)
Townsend Index, mean (SD)	-1.1 (3.0)	-1.0 (3.2)	-0.3 (3.3)
Smoking, No. (%)			
Never	1223 (51.4)	1251 (52.2)	1383 (49.1)
Former	923 (38.8)	920 (38.4)	1068 (37.9)
Current	233 (9.8)	225 (9.4)	367 (13.0)
Family history of CVD, cancer or diabetes (yes), No. (%)	2033 (85.5)	2007 (83.8)	2381 (84.5)
Statins (yes), No. (%)	1449 (60.9)	1422 (59.3)	1634 (58.0)
Use of blood-pressure lowering drugs, No (%)			
0	1526 (64.1)	1513 (63.1)	1862 (66.1)
1	505 (21.2)	523 (21.8)	577 (20.5)
2	279 (11.7)	279 (11.6)	292 (10.4)
3 or more	69 (2.9)	81 (3.4)	87 (3.1)
Doctor diagnosis or on treatment for type 2 diabetes (yes), No. (%)**	1838 (77.3)	1838 (76.7)	2155 (76.5)
Use of blood-glucose lowering drugs, No (%)***			
None	550 (29.9)	526 (28.6)	636 (29.5)
Insulin only	101 (5.5)	77 (4.2)	85 (3.9)
Non-insulin only	1059 (57.6)	1101 (59.9)	1287 (59.7)
Insulin and non-insulin	128 (7.0)	134 (7.3)	147 (6.8)
China Kadoorie Biobank			
% Women	2321 (30.9)	1156 (39.0)	1654 (34.3)
Age (years), mean (SD)	49.4 (7.2)	49.2 (7.2)	49.0 (7.0)
Body mass index (kg/m^2), mean (SD)	25.8 (3.3)	25.5 (3.3)	25.1 (3.4)

Supplementary Table 9. Descriptive characteristics by occupational physical activity in adults with type 2 diabetes in employment

LTPA (MET-hours/wk), mean (SD)	7.5 (14.7)	6.0 (14.9)	3.7 (10.2)
Participation in heavy physical activity/exercise, No. (%)****	205 (8.8)	126 (10.9)	272 (16.4)
Duration of diabetes (years), mean (SD)	2.4 (3.7)	1.6 (2.9)	1.7 (3.1)
Education, No. (%)			· · ·
No school or primary school	330 (14.2)	345 (29.8)	641 (38.8)
Middle school	716 (30.8)	438 (37.9)	613 (37.1)
High school or higher	1275 (54.9)	373 (32.3)	400 (24.2)
Smoking, No. (%)			
Never	961 (41.4)	539 (46.6)	670 (40.5)
Occasional	184 (7.9)	85 (7.4)	117 (7.1)
Former	224 (9.7)	99 (8.6)	173 (10.5)
Current	952 (41.0)	433 (37.5)	694 (42.0)
Family history of CVD, cancer or diabetes (yes), No. (%)	1342 (57.8)	612 (52.9)	838 (50.7)
Statins (yes), No. (%)	7 (0.3)	7 (0.6)	2 (0.1)
Use of blood-pressure lowering drugs, No (%)			
0	2146 (92.5)	1082 (93.6)	1547 (93.5)
1	154 (6.6)	65 (5.6)	90 (5.4)
2 or more	21 (0.9)	9 (0.8)	17 (1.0)
Doctor diagnosis or on treatment for type 2 diabetes (yes), No. (%)*	1132 (48.8)	446 (38.6)	644 (38.9)
Use of blood-glucose lowering drugs, No (%)**			
None	392 (34.6)	199 (44.6)	266 (41.3)
Insulin only	157 (13.9)	27 (6.1)	55 (8.5)
Chlorpropamide or metformin only	564 (49.8)	209 (46.9)	313 (48.6)
Insulin and Chlorpropamide or metformin	19 (1.7)	11 (2.5)	10 (1.6)

LTPA: leisure-time physical activity, MET: metabolic equivalent, CVD: cardiovascular disease

\*Participants reporting any heavy manual work in UK Biobank. Combining 'manual work' and 'heavy manual work' in China Kadoorie Biobank

\*\*Individuals with type 2 diabetes identified from self-report or use of glucose-lowering drugs Eastwood et al., 2016, UKB Biobank) or from self-reported diagnosis of diabetes from a doctor (China Kadoorie Biobank).

\*\*\*Individuals identified with type 2 diabetes solely from measured Hba1c (UK Biobank) or random blood glucose (China Kadoorie Biobank) are not included in the denominator.

\*\*\*\*Includes work, transportation, domestic and leisure activities

Supplementary Table 10. Physical activity for transportation to work and all-cause mortality and cardiovascular disease among adults with type 2 diabetes in employment

	Ref		
	(Passive	Walking	Cycling
	transportation)		
	All-cause m	ortality	1
UK Biobank			
N = 7593, deaths = 549*	5817 / 415	866 / 61	248 / 9
Crude incidence rate/1000 person-vears	7.7 (7.0, 8.4)	7.5 (5.9, 9.7)	3.9 (2.0, 7.5)
Model 1 (HR [95%CI])	1 [reference]	1.10 (0.84, 1.44)	0.56 (0.29, 1.09)
Model 2 (HR [95%CI])	1 [reference]	1.07 (0.82, 1.41)	0.58 (0.30, 1.13)
Model 3 (HR [95%CI])	1 [reference]	1.12 (0.85, 1.48)	0.63 (0.32, 1.22)
Model 4 (HR [95%CI])	1 [reference]	1.12 (0.85, 1.47)	0.61 (0.32, 1.19)
China Kadoorie Biobank			
N = 5131, deaths = 284*	2229 / 104	990 / 65	1000 / 53
Crude incidence rate/1000	6.6 (5.4, 8.0)	9.6 (7.5, 12.2)	7.6 (5.8, 9.9)
person-years			
Model 1 (HR [95%CI])	1 [reference]	1.42 (1.04, 1.95)	1.00 (0.71, 1.40)
Model 2 (HR [95%CI])	1 [reference]	1.25 (0.91, 1.72)	0.94 (0.67, 1.32)
Model 3 (HR [95%CI])	1 [reference]	1.25 (0.91, 1.72)	0.94 (0.66, 1.32)
Model 4 (HR [95%CI])	1 [reference]	1.25 (0.91, 1.72)	0.94 (0.67, 1.33)
	Cardiovascula	r mortality	I
			212/2
N = 7593, deaths = 158*	5817/119	866 / 15	248/6
Crude incidence rate/1000	2.2 (1.8, 2.6)	1.9 (1.1, 3.1)	2.6 (1.2, 5.8)
Model 1 (HR [95%CII)	1 [reference]	0.97 (0.56, 1.67)	1 32 (0 58 3 00)
Model 2 (HR [95%CI])	1 [reference]	0.95 (0.55, 1.64)	1 44 (0 63 3 29)
Model 3 (HR [95%CI])	1 [reference]		1.61 (0.70, 3.67)
Model 4 (HR [95%CI])	1 [reference]	1 00 (0 58 1 74)	1.53 (0.66, 3.54)
China Kadoorie Biobank			
N = 5131, deaths = 99*	2229 / 34	990 / 22	1000 / 21
Crude incidence rate/1000	2.8 (2.3, 3.4)	2.7 (2.2, 3.3)	2.7 (2.2, 3.3)
person-years			
Model 1 (HR [95%CI])	1 [reference]	1.53 (0.89, 2.65)	0.91 (0.44, 1.87)
Model 2 (HR [95%CI])	1 [reference]	1.26 (0.72, 2.19)	0.74 (0.35, 1.53)
Model 3 (HR [95%CI])	1 [reference]	1.27 (0.73, 2.21)	0.78 (0.38, 1.63)
Model 4 (HR [95%CI])	1 [reference]	1.20 (0.68, 2.21)	0.80 (0.38, 1.69)
	Major advarga pardia	vacaular overte	
IIK Biobank	Major auverse caruic		
N = 7365 cases = 1055*	56/3 / 823	8/1 / 101	244/30
N = 7305, cases = 1055	167 (156 178)		
person-vears	10.7 (13.0, 17.0)	10.0 (11.1, 10.4)	13.0 (3.0, 13.7)
Model 1 (HR [95%CII)	1 [reference]	0.88 (0.72, 1.09)	0.87 (0.60, 1.25)
Model 2 (HR [95%CI])	1 [reference]	0.87 (0.70, 1.07)	0.91 (0.63, 1.32)
Model 3 (HR [95%CII)	1 [reference]	0.90 (0.73. 1.12)	0.98 (0.68. 1.41)
Model 4 (HR [95%CI])	1 [reference]	0.90 (0.73, 1.12)	0.96 (0.66, 1.38)
		(, ···-/	(,,
China Kadoorie Biobank			
N = 4919, deaths = 875*	2136 / 362	940 / 184	969 / 150
Crude incidence rate/1000	25.9 (23.4, 28.7)	31.0 (26.8, 35.8)	23.5 (20.0, 27.6)
person-years			
Model 1 (HR [95%CI])	1 [reference]	1.19 (0.99, 1.42)	0.89 (0.74, 1.08)

Model 2 (HR [95%CI])	1 [reference]	1.08 (0.89, 1.30)	0.89 (0.73, 1.08)
Model 3 (HR [95%CI])	1 [reference]	1.08 (0.90, 1.31)	0.93 (0.77, 1.13)
Model 4 (HR [95%CI])	1 [reference]	1.06 (0.88, 1.28)	0.93 (0.77, 1.13)

HR: hazard ratio, sHR: subdistribution hazard ratio

In UK Biobank, participants using mixed modes are coded according to their active transportation. Participants reporting any cycling are coded as cyclist. Only the primary mode of transportation is reported in China Kadoorie Biobank. \*Total also includes individuals working from home.

Model 1: adjusted for sex and age (time-scale).

Model 2: Multivariable-adjusted,

UK Biobank: Model 1 + education (no qualifications, qualifications, not college/university degree, college/university degree), Townsend deprivation index (continuous), living with partner (yes/no), ethnicity (European, South Asian, African Caribbean, other), employment (sedentary work, some standing and no heavy work, heavy manual work, not in employment, retired), smoking (never, former, current), alcohol intake (never, former, current-<3 times/week, current->3 times/week), diet quality index (0, 1, 2-3), body mass index (continuous), family history of diabetes, cardiovascular disease, or cancer (yes/no), inclusion method (self-reported type 2 diabetes/use of medication or biochemistry), depression (yes/no), loneliness (yes/no), diabetes duration (continuous), leisure-time physical activity (continuous),

China Kadoorie Biobank: Model 1 + education (no school or primary school, middle school, High school or higher), household income (<10,000 yuan/y, 10,000-19,999 yuan/y, 20,000-34,999 yuan/y,  $\geq$ 35,000 yuan/y), marital status (married, yes/no), has health cover (yes/no), employment (sedentary, standing, manual work, not in employment, retired), smoking (never, occasional, former regular, current), alcohol intake (never/occasionally, former weekly, current, <3 days/week, current  $\geq$ 3 days/week), regular fruit consumption ( $\geq$ 4 days/week, yes/no), regular meat consumption ( $\geq$ 4 days/week, yes/no), body mass index (continuous), family history of diabetes, cardiovascular disease, or cancer (yes/no), inclusion method (self-report or biochemistry), experienced food shortage with weight loss (yes/no), major depression in last 12 months (yes/no), diabetes duration (continuous), leisure-time physical activity (continuous).

Model 3: Model 2 + adjustment for body mass index

Model 4: Model 3 + adjustment for use of glucose-lowering drugs, statins, and blood-pressure-lowering drugs

Occessing         Distribution         Distribution         Distribution           UK Biobank         2379 / 144         2396 / 183         2818 / 222           Crude incidence rate/1000         6.5 (5.5, 7.7)         8.2 (7.1, 9.5)         8.5 (7.4, 9.7)           person-years         1         1 (148 (95%CII)         1 [reference]         1.14 (0.92, 1.42)         1.23 (1.00, 1.52)           Model 1 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 2 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 3 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 1 (HR [95%CII)         1 [reference]         0.90 (0.65, 1.24)         1.36 (1.04, 1.76)           Model 1 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.94, 1.75)           Model 1 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.94, 1.75)           Model 4 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.94, 1.75)           Model 4 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.94, 1.75)           Model 1 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.98, 1.75)     <		Sedentary	Standing/walking	Manual work*				
UK Biobank         Interfactors informatly           N = 7593, deaths = 549         2379 / 144         2396 / 183         2818 / 222           Crude incidence rate/1000         6.5 (5.5, 7.7)         8.2 (7.1, 9.5)         8.5 (7.4, 9.7)           Model 1 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.42)         1.23 (1.00, 1.52)           Model 2 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.43)         1.16 (0.93, 1.45)           Model 3 (HR [95%CII)         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           China Kadoorie Biobank         -         -         -           N = 5131, deaths = 284         2331 / 125         1156 / 53         1654 / 106           Crude incidence rate/1000         7.6 (6.4, 9.1)         6 (6.50, 8.6)         9.2 (7.6, 11.2)           Model 1 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 1 (HR [95%CII)         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 1 (HR [95%CII)         1 [reference]         1.28 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 1 (HR [95%CII)         1 [reference]         1.28 (0.83, 2.01)         1.57 (1.								
Ort Didatin         Display         2379 / 144         2396 / 183         2818 / 222           Crude incidence rate/1000         6.5 (5.5, 7.7)         8.2 (7.1, 9.5)         8.5 (7.4, 9.7)           Person-years         1         1 (14 (0.92, 1.42)         1.23 (10.0, 1.52)           Model 1 (HR [95%CI])         1 [reference]         1.14 (0.92, 1.42)         1.23 (10.0, 1.52)           Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.16 (0.93, 1.45)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.33 (1.04, 1.76)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         1.26 (0.61, 2.9)         1.23 (0.99, 1.75)								
N = 793, 08410 ± 949         2379 / 144         2396 / 163         2010 / 1222           Crude incidence rate/100         6.5 (5.5, 7.7)         8.2 (7.1, 9.5)         8.5 (7.4, 9.7)           Model 1 (HR [95%CI])         1 [reference]         1.14 (0.92, 1.42)         1.23 (1.00, 1.52)           Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.16 (0.93, 1.45)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           China Kadoorie Biobank         0         0         0.6 (5.0, 8.6)         9.2 (7.6, 11.2)           Crude incidence rate/1000         7.6 (6.4, 9.1)         6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.24)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.74)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.74)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 4 (HR [95%CI]) </td <td>N 7502 deaths 540</td> <td>2270 / 4 4 4</td> <td>2200 / 4.02</td> <td>2040 ( 222</td>	N 7502 deaths 540	2270 / 4 4 4	2200 / 4.02	2040 ( 222				
Clube incluence failer foru         6.3 (5.5, 7.7)         6.3 (7.1, 9.3)         6.3 (7.1, 9.3)           Model 1 (HR [95%CI])         1 [reference]         1.14 (0.92, 1.42)         1.23 (1.00, 1.52)           Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.15 (0.92, 1.44)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.45)           Model 4 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 4 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Model 1 (HR [95%CI])         1 [reference]         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.32, .53)           Model 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.76 (1.02, .24)	N = 7593, dealins = 549		2390 / 103					
Derson-years         Ireference         1.14 (0.92, 1.42)         1.23 (1.00, 1.52)           Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.15 (0.92, 1.43)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.16 (0.93, 1.45)           Model 4 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           China Kadoorie Biobank         1         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.29)         1.32 (0.99, 1.75)         Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.91, 1.75)           Model 1 (HR [95%CI])         1 [refere	Crude incidence rate/1000	6.5 (5.5, 7.7)	8.2 (7.1, 9.5)	8.5 (7.4, 9.7)				
Model 1 (HR [95%CI])         1 [reference]         1.14 (0.92, 1.42)         1.25 (1.00, 1.52)           Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.15 (0.92, 1.44)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           China Kadoorie Biobank               Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.29)         1.32 (0.99, 1.75)         Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.9 (2.3, 3.6)           person-years           1.70 (1.13, 2.53)           Model 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)	person-years			4 00 (4 00 4 50)				
Model 2 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.16 (0.92, 1.44)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.45)           Model 3 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.45)           China Kadoorie Biobank          1.15 (0.92, 1.43)         1.17 (0.93, 1.45)           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.74)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.74)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         1.28 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 3 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI	Model 1 (HR [95%CI])	1 [reference]	1.14 (0.92, 1.42)	1.23 (1.00, 1.52)				
Model 3 (HR [95%CI])         1 [reference]         1.16 (0.33, 1.45)         1.17 (0.33, 1.46)           China Kadoorie Biobank                1.17 (0.33, 1.46)           China Kadoorie Biobank             1.16 (0.33, 1.45)          1.17 (0.33, 1.46)           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)          person-years           1.35 (1.04, 1.76)          Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)         Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)         Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)         Model 1 (HR [95%CI])         1 [reference]         1.26 (1.6, 2.9)         2.9 (2.3, 3.6)           Person-years             1.75 (1.02, 2.41)         Model 1 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.5 (1.02, 2.43)           Model 1 (HR [95%CI])         1 [reference]         1.30 (0.33, 2.02)         1.62 (1.05, 2.48)	Model 2 (HR [95%CI])	1 [reference]	1.15 (0.92, 1.43)	1.15 (0.92, 1.44)				
Model 4 (HR [95%CI])         1 [reference]         1.15 (0.92, 1.43)         1.17 (0.93, 1.46)           China Kadoorie Biobank           1156 / 53         1654 / 106           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 2 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.43)           Model 3 (HR [95	Model 3 (HR [95%CI])	1 [reference]	1.16 (0.93, 1.45)	1.16 (0.93, 1.45)				
China Kadoorie Biobank         China Kadoorie Biobank           N = 5131, deaths = 284         2331 / 125         1156 / 53         1654 / 106           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (50, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 1 (HR [95%CI)         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI)         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           Nodel 1 (HR [95%CI)         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 1 (HR [95%CI)         1 [reference]         1.29 (0.83, 2.01)         1.67 (1.02, 2.41)           Model 2 (HR [95%CI)         1 [reference]         1.32 (0.83, 2.06)         1.62 (1.05, 2.48)           Model 3 (HR [95%CI)         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI)         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           China Kadoorie Biobank           N = 5131, deaths = 99         2.321 / 44         1156 / 20         1654 / 35           Crude incidence rate/1000 </td <td>Model 4 (HR [95%CI])</td> <td>1 [reference]</td> <td>1.15 (0.92, 1.43)</td> <td>1.17 (0.93, 1.46)</td>	Model 4 (HR [95%CI])	1 [reference]	1.15 (0.92, 1.43)	1.17 (0.93, 1.46)				
China Kadoorie Biobank         Image: China Kadoorie Biobank           N= 5131, deaths = 284         2331 / 125         1156 / 53         1654 / 106           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Model 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0								
N = 5131, deaths = 284         2331 / 125         1156 / 53         1654 / 106           Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 1 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years           Model 1 (HR [95%CI])           1 [reference]         1.32 (0.83, 2.00)         1.67 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.32 (0.83, 2.02)         1.65 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93) </td <td>China Kadoorie Biobank</td> <td></td> <td></td> <td></td>	China Kadoorie Biobank							
Crude incidence rate/1000         7.6 (6.4, 9.1)         6.6 (5.0, 8.6)         9.2 (7.6, 11.2)           person-years         1 [reference]         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         0         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.01)         1.62 (1.05, 2.48)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (	N = 5131, deaths = 284	2331 / 125	1156 / 53	1654 / 106				
person-years	Crude incidence rate/1000	7.6 (6.4, 9.1)	6.6 (5.0, 8.6)	9.2 (7.6, 11.2)				
Model 1 (HR [95%CI])         1 [reference]         0.90 (0.65, 1.24)         1.35 (1.04, 1.76)           Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           Cardiovascular mortality           UK Biobank           Nodel 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 1 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 2 (	person-years							
Model 2 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         1         [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 1 (HR [95%CI])         1 [reference]         1.32 (0.85, 2.06)         1.62 (1.05, 2.48)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           China Kadoorie Biobank         1         1         1.76 reference]         1.09 (0.81, 1.79)         1.19 (0.73, 1.94)           Model 1 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)         1.90 (73, 1.94)           Model 2 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.80)<	Model 1 (HR [95%CI])	1 [reference]	0.90 (0.65, 1.24)	1.35 (1.04, 1.76)				
Model 3 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.32 (0.99, 1.75)           Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank           N = 7533, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         0         1.70 (1.13, 2.53)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.32 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.32 (0.83, 2.02)         1.62 (1.05, 2.49)           Model 4 (HR [95%CI])         1 [reference]         1.32 (0.83, 2.02)         1.62 (1.05, 2.49)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 1 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 1 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.77, 1.93)            Major a	Model 2 (HR [95%CI])	1 [reference]	0.92 (0.66, 1.29)	1.32 (0.99, 1.75)				
Model 4 (HR [95%CI])         1 [reference]         0.92 (0.66, 1.29)         1.31 (0.99, 1.74)           Cardiovascular mortality           UK Biobank	Model 3 (HR [95%CI])	1 [reference]	0.92 (0.66, 1.29)	1.32 (0.99, 1.75)				
Cardiovascular mortality           UK Biobank           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         1         1         [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 1 (HR [95%CI])         1         [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 2 (HR [95%CI])         1         [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1         [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           China Kadoorie Biobank         1         [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           Crude incidence rate/1000         2.8 (2.3, 3.4)         2.8 (2.3, 3.4)         2.7 (2.2, 3.3)           person-years         1         [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1         [reference]         1.06 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 3 (HR [95%CI])         1         [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Model 2 (HR [95%CI])         1         <	Model 4 (HR [95%CI])	1 [reference]	0.92 (0.66, 1.29)	1.31 (0.99, 1.74)				
Cardiovascular mortality           UK Biobank         Cardiovascular mortality           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         1         1 (reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 1 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           China Kadoorie Biobank               N = 5131, deaths = 99         2321 / 44         1156 / 20         1654 / 35           Crude incidence rate/1000         2.8 (2.3, 3.4)         2.7 (2.2, 3.3)            person-years         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)            Model 1 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 2 (HR [95%CI])         1 [reference]		<b>-</b>						
UK Biobank         2396 / 48         2316 / 48           N = 7593, deaths = 158         2379 / 35         2396 / 48         2818 / 75           Crude incidence rate/1000         1.6 (1.1, 2.2)         2.6 (1.6, 2.9)         2.9 (2.3, 3.6)           person-years         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)         Model 2 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 2 (HR [95%CI])         1 [reference]         1.32 (0.85, 2.06)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           China Kadoorie Biobank         1         1.62 (1.05, 2.48)         1.62 (1.05, 2.49)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           Model 4 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Model 2 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.		Cardiovascula	r mortality					
N = 7593, deaths = 158       2379 / 35       2396 / 48       2818 / 75         Crude incidence rate/1000       1.6 (1.1, 2.2)       2.6 (1.6, 2.9)       2.9 (2.3, 3.6)         person-years       1.26 (0.81, 1.94)       1.70 (1.13, 2.53)         Model 2 (HR [95%CI])       1 [reference]       1.29 (0.83, 2.01)       1.57 (1.02, 2.41)         Model 3 (HR [95%CI])       1 [reference]       1.32 (0.85, 2.06)       1.62 (1.05, 2.48)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         China Kadoorie Biobank	UK Biobank							
Arrore incidence rate/1000       1.6 (1.1, 2.2)       2.6 (1.6, 2.9)       2.9 (2.3, 3.6)         Model 1 (HR [95%CI])       1 [reference]       1.26 (0.81, 1.94)       1.70 (1.13, 2.53)         Model 2 (HR [95%CI])       1 [reference]       1.29 (0.83, 2.01)       1.57 (1.02, 2.41)         Model 3 (HR [95%CI])       1 [reference]       1.32 (0.85, 2.06)       1.62 (1.05, 2.48)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.48)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         China Kadoorie Biobank             N = 5131, deaths = 99       2321 / 44       1156 / 20       1654 / 35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years             Model 1 (HR [95%CI])       1 [reference]       0.97 (0.57, 1.63)       1.22 (0.77, 1.93)         Model 2 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.80)       1.22 (0.75, 1.97)         Model 4 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Model 4 (HR [95%CI])       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 1 (HR [95%CI])	N = 7593 deaths = 158	2379 / 35	2396 / 48	2818 / 75				
Discrete Notes Notes Notes         The (Tri, LL)         Lis (Tri, Ll)         Lis (Tri, Ll)           Model 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.32 (0.85, 2.06)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.65 (1.05, 2.48)           N = 5131, deaths = 99         2321 / 44         1156 / 20         1654 / 35           Crude incidence rate/1000         2.8 (2.3, 3.4)         2.8 (2.3, 3.4)         2.7 (2.2, 3.3)           person-years         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 1 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.75, 1.97)           Model 3 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.90 (73, 1.94)           Model 4 (HR [95%CI])	Crude incidence rate/1000	16(1122)	26(1629)	29(2336)				
Model 1 (HR [95%CI])         1 [reference]         1.26 (0.81, 1.94)         1.70 (1.13, 2.53)           Model 2 (HR [95%CI])         1 [reference]         1.29 (0.83, 2.01)         1.57 (1.02, 2.41)           Model 3 (HR [95%CI])         1 [reference]         1.32 (0.85, 2.06)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.48)           Model 4 (HR [95%CI])         1 [reference]         1.30 (0.83, 2.02)         1.62 (1.05, 2.49)           China Kadoorie Biobank              N = 5131, deaths = 99         2321 / 44         1156 / 20         1654 / 35           Crude incidence rate/1000         2.8 (2.3, 3.4)         2.8 (2.3, 3.4)         2.7 (2.2, 3.3)           person-years          0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 1 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.90 (.73, 1.94)           Model 1 (HR [95%CI])         1 [reference] <td>person-years</td> <td>1.0 (1.1, 2.2)</td> <td>2.0 (1.0, 2.0)</td> <td>2.0 (2.0, 0.0)</td>	person-years	1.0 (1.1, 2.2)	2.0 (1.0, 2.0)	2.0 (2.0, 0.0)				
Model 2 (HR [95%CI])       1 [reference]       1.20 (0.83, 2.01)       1.57 (1.02, 2.41)         Model 3 (HR [95%CI])       1 [reference]       1.32 (0.85, 2.06)       1.62 (1.05, 2.48)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.48)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         China Kadoorie Biobank         N = 5131, deaths = 99       2321 / 44       1156 / 20       1654 / 35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years       0.97 (0.57, 1.63)       1.22 (0.77, 1.93)         Model 1 (HR [95%CI])       1 [reference]       1.04 (0.61, 1.79)       1.19 (0.73, 1.94)         Model 3 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.80)       1.22 (0.75, 1.97)         Model 4 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Major adverse cardiovascular events         UK Biobank         N = 7365, cases = 1055       2323 / 276       2334 / 343       2708 / 436         Crude incidence rate/1000       13.4 (11.9, 15.1)       16.9 (15.2, 18.8)       18.5 (16.8, 20.3)         person-years       1.20 (1.02, 1.40)       1.33 (1.	Model 1 (HR [95%CII)	1 [reference]	1 26 (0 81 1 94)	1 70 (1 13 2 53)				
Inded 2 (Int [95/60])       1 [reference]       1.23 (0.26, 2.07)       1.37 (1.32, 2.47)         Model 3 (Int [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.48)         Model 4 (Int [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         China Kadoorie Biobank         N = 5131, deaths = 99       2321 / 44       1156 / 20       1654 / 35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years       0.97 (0.57, 1.63)       1.22 (0.77, 1.93)         Model 3 (Int [95%CI])       1 [reference]       1.04 (0.61, 1.79)       1.19 (0.73, 1.94)         Model 3 (Int [95%CI])       1 [reference]       1.05 (0.61, 1.80)       1.22 (0.75, 1.97)         Model 4 (Int [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Major adverse cardiovascular events         UK Biobank         N = 7365, cases = 1055       2323 / 276       2334 / 343       2708 / 436         Crude incidence rate/1000       13.4 (11.9, 15.1)       16.9 (15.2, 1.8.8)       18.5 (16.8, 20.3)         person-years       13.4 (11.9, 15.1)       16.9 (15.2, 1.45)       1.36 (1.16, 1.60)         Model 1 (IHR [95%CI])       1 [reference]	Model 2 (HR [95%CI])	1 [reference]		1.70 (1.13, 2.33)				
Model 3 (IR [95%CI])       1 [reference]       1.32 (0.63, 2.00)       1.02 (1.05, 2.49)         Model 4 (HR [95%CI])       1 [reference]       1.30 (0.83, 2.02)       1.62 (1.05, 2.49)         China Kadoorie Biobank            N = 5131, deaths = 99       2321 / 44       1156 / 20       1654 / 35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years             Model 1 (HR [95%CI])       1 [reference]       0.97 (0.57, 1.63)       1.22 (0.77, 1.93)         Model 2 (HR [95%CI])       1 [reference]       1.04 (0.61, 1.79)       1.19 (0.73, 1.94)         Model 3 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.80)       1.22 (0.75, 1.97)         Model 4 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Model 4 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Model 1 (HR [95%CI])       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 1 (HR [95%CI])       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 2 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 2 (HR [95%CI	Model 2 (HR [95%CI])	1 [reference]	1.29 (0.03, 2.01)	1.62 (1.05, 2.41)				
Image: A (IIK [95/3c1])       Image: Project (IIC)	Model 4 (HR [95%CI])	1 [reference]	1.32 (0.83, 2.00)	1.62 (1.05, 2.40)				
China Kadoorie Biobank		I [IEIEIEIICE]	1.30 (0.83, 2.02)	1.02 (1.03, 2.49)				
N = 5131, deaths = 99       2321 / 44       1156 / 20       1654 / 35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years	China Kadaaria Biahank							
N = 5131, deams = 99       2321/44       1136/20       1654/35         Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         person-years		2221 / 11	1150 / 20	4054/05				
Crude incidence rate/1000       2.8 (2.3, 3.4)       2.8 (2.3, 3.4)       2.7 (2.2, 3.3)         Model 1 (HR [95%CI])       1 [reference]       0.97 (0.57, 1.63)       1.22 (0.77, 1.93)         Model 2 (HR [95%CI])       1 [reference]       1.04 (0.61, 1.79)       1.19 (0.73, 1.94)         Model 3 (HR [95%CI])       1 [reference]       1.05 (0.61, 1.80)       1.22 (0.75, 1.97)         Model 4 (HR [95%CI])       1 [reference]       1.06 (0.61, 1.83)       1.19 (0.73, 1.94)         Major adverse cardiovascular events         UK Biobank         N = 7365, cases = 1055       2323 / 276       2334 / 343       2708 / 436         Crude incidence rate/1000       13.4 (11.9, 15.1)       16.9 (15.2, 18.8)       18.5 (16.8, 20.3)         person-years       1       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 1 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 2 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 3 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 3 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.39 (1.18, 1.64)         China Kadoorie Biobank         N =	N = 5131, deaths = 99	2321/44		1654 / 35				
person-years         Interference         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Major adverse cardiovascular events           UK Biobank           N = 7365, cases = 1055         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years         1         1.20 (1.02, 1.40)         1.33 (1.14, 1.55)           Model 1 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4	Crude Incidence rate/1000	2.8 (2.3, 3.4)	2.8 (2.3, 3.4)	2.7 (2.2, 3.3)				
Model 1 (HR [95%CI])         1 [reference]         0.97 (0.57, 1.63)         1.22 (0.77, 1.93)           Model 2 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Major adverse cardiovascular events           UK Biobank           N = 7365, cases = 1055         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years	person-years			4 00 (0 77 4 00)				
Model 2 (HR [95%CI])         1 [reference]         1.04 (0.61, 1.79)         1.19 (0.73, 1.94)           Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Major adverse cardiovascular events           UK Biobank           N = 7365, cases = 1055         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years         1         1.22 (1.04, 1.43)         1.34 (1.14, 1.55)           Model 1 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           China Kadoorie Biobank         V         V         V         V           N = 4919, deaths = 875*         2199 / 445         1117 / 171         1603 / 259           Crude incidence rate/1000         31.5 (28.7, 34.4)         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           person-years         0	Model 1 (HR [95%CI])	1 [reference]	0.97 (0.57, 1.63)	1.22 (0.77, 1.93)				
Model 3 (HR [95%CI])         1 [reference]         1.05 (0.61, 1.80)         1.22 (0.75, 1.97)           Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Major adverse cardiovascular events         Major adverse cardiovascular events           UK Biobank	Model 2 (HR [95%CI])	1 [reference]	1.04 (0.61, 1.79)	1.19 (0.73, 1.94)				
Model 4 (HR [95%CI])         1 [reference]         1.06 (0.61, 1.83)         1.19 (0.73, 1.94)           Major adverse cardiovascular events         Major adverse cardiovascular events           UK Biobank         Major adverse cardiovascular events           UK Biobank         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years         1.20 (1.02, 1.40)         1.33 (1.14, 1.55)         1.33 (1.14, 1.55)           Model 1 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           China Kadoorie Biobank         N         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           Person-years         Model 1 (HR [95%CI])         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 2 (HR [95%CI])         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 2 (HR [95%CI])         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 3 (HR [95%CI])         1 [reference]	Model 3 (HR [95%CI])	1 [reference]	1.05 (0.61, 1.80)	1.22 (0.75, 1.97)				
Major adverse cardiovascular events           UK Biobank         Ange adverse cardiovascular events           N = 7365, cases = 1055         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years         1         110 (1.02, 1.40)         1.33 (1.14, 1.55)           Model 1 (HR [95%CI])         1 [reference]         1.20 (1.02, 1.40)         1.33 (1.14, 1.55)           Model 2 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           China Kadoorie Biobank         Image additional state additionadditis additional state additional state additional sta	Model 4 (HR [95%CI])	1 [reference]	1.06 (0.61, 1.83)	1.19 (0.73, 1.94)				
Major adverse cardiovascular events           UK Biobank         Image: Major adverse cardiovascular events           N = 7365, cases = 1055         2323 / 276         2334 / 343         2708 / 436           Crude incidence rate/1000         13.4 (11.9, 15.1)         16.9 (15.2, 18.8)         18.5 (16.8, 20.3)           person-years         Image: Model 1 (HR [95%CI])         1 [reference]         1.20 (1.02, 1.40)         1.33 (1.14, 1.55)           Model 2 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.24 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         0.23 (1.02, 27.2)         24.8 (22.0, 28.0)           Person-years         Image: main calculation of the properties of the properies of the proper								
UK Biobank         Image: Constraint of the system of	Major adverse cardiovascular events							
N = 7365, cases = 1055       2323 / 276       2334 / 343       2708 / 436         Crude incidence rate/1000       13.4 (11.9, 15.1)       16.9 (15.2, 18.8)       18.5 (16.8, 20.3)         person-years       1       1       [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 1 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 2 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 3 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       0.23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years       0       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years       0       0.77 (0.65, 0.92)       0.82 (0.71, 0.96)       0.94 (0.80, 1.11)         Model 1 (HR [95%CI])       1 [reference]       0.87 (0.73, 1.04)       0.94 (0.80, 1.11)         Model 2 (HR [95%CI]	UK Biobank							
Crude incidence rate/1000 person-years       13.4 (11.9, 15.1)       16.9 (15.2, 18.8)       18.5 (16.8, 20.3)         Model 1 (HR [95%CI])       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 2 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 3 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.02, 27.2)       24.8 (22.0, 28.0)         Model incidence rate/1000       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years       1       1 [reference]       0.77 (0.65, 0.92)       0.82 (0.71, 0.96)         Model 1 (HR [95%CI])       1 [reference]       0.87 (0.73, 1.04)       0.94 (0.80, 1.11)         Model 2 (HR [95%CI])       1 [reference]       0.88 (0 74 1.05)       0.97 (0 82 1.14)	N = 7365, cases = 1055	2323 / 276	2334 / 343	2708 / 436				
person-years         Image: constraint of the system           Model 1 (HR [95%CI])         1 [reference]         1.20 (1.02, 1.40)         1.33 (1.14, 1.55)           Model 2 (HR [95%CI])         1 [reference]         1.22 (1.04, 1.43)         1.34 (1.14, 1.58)           Model 3 (HR [95%CI])         1 [reference]         1.24 (1.05, 1.45)         1.36 (1.16, 1.60)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         1 [reference]         1.23 (1.05, 1.45)         1.39 (1.18, 1.64)           Model 4 (HR [95%CI])         31.5 (28.7, 34.4)         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           person-years	Crude incidence rate/1000	13.4 (11.9, 15.1)	16.9 (15.2, 18.8)	18.5 (16.8, 20.3)				
Model 1 (HR [95%CI])       1 [reference]       1.20 (1.02, 1.40)       1.33 (1.14, 1.55)         Model 2 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 3 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         Model 5 (HR [95%CI])       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years	person-years							
Model 2 (HR [95%CI])       1 [reference]       1.22 (1.04, 1.43)       1.34 (1.14, 1.58)         Model 3 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         China Kadoorie Biobank         N = 4919, deaths = 875*       2199 / 445       1117 / 171       1603 / 259         Crude incidence rate/1000       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years	Model 1 (HR [95%CI])	1 [reference]	1.20 (1.02, 1.40)	1.33 (1.14, 1.55)				
Model 3 (HR [95%CI])       1 [reference]       1.24 (1.05, 1.45)       1.36 (1.16, 1.60)         Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         China Kadoorie Biobank         N = 4919, deaths = 875*       2199 / 445       1117 / 171       1603 / 259         Crude incidence rate/1000       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years       0.77 (0.65, 0.92)       0.82 (0.71, 0.96)         Model 1 (HR [95%CI])       1 [reference]       0.77 (0.65, 0.92)       0.82 (0.71, 0.96)         Model 2 (HR [95%CI])       1 [reference]       0.87 (0.73, 1.04)       0.94 (0.80, 1.11)         Model 3 (HR [95%CI])       1 [reference]       0.88 (0 74 1 05)       0.97 (0 82 1 14)	Model 2 (HR [95%CI])	1 [reference]	1.22 (1.04, 1.43)	1.34 (1.14, 1.58)				
Model 4 (HR [95%CI])       1 [reference]       1.23 (1.05, 1.45)       1.39 (1.18, 1.64)         China Kadoorie Biobank            N = 4919, deaths = 875*       2199 / 445       1117 / 171       1603 / 259         Crude incidence rate/1000       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years             Model 1 (HR [95%CI])       1 [reference]       0.77 (0.65, 0.92)       0.82 (0.71, 0.96)         Model 2 (HR [95%CI])       1 [reference]       0.87 (0.73, 1.04)       0.94 (0.80, 1.11)         Model 3 (HR [95%CI])       1 [reference]       0.88 (0 74 1 05)       0.97 (0.82 1 14)	Model 3 (HR [95%CI])	1 [reference]	1.24 (1.05, 1.45)	1.36 (1.16, 1.60)				
China Kadoorie Biobank         China Kadoorie Biobank           N = 4919, deaths = 875*         2199 / 445         1117 / 171         1603 / 259           Crude incidence rate/1000         31.5 (28.7, 34.4)         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           person-years         0         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 1 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0 74 1 05)         0.97 (0.82 1 14)	Model 4 (HR [95%CI])	1 [reference]	1.23 (1.05, 1.45)	1.39 (1.18, 1.64)				
China Kadoorie Biobank         1117 / 171         1603 / 259           N = 4919, deaths = 875*         2199 / 445         1117 / 171         1603 / 259           Crude incidence rate/1000         31.5 (28.7, 34.4)         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           person-years         0         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 1 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0.74, 1.05)         0.97 (0.82, 1.14)								
N = 4919, deaths = 875*       2199 / 445       1117 / 171       1603 / 259         Crude incidence rate/1000       31.5 (28.7, 34.4)       23.4 (20.2, 27.2)       24.8 (22.0, 28.0)         person-years	China Kadoorie Biobank							
Crude incidence rate/1000         31.5 (28.7, 34.4)         23.4 (20.2, 27.2)         24.8 (22.0, 28.0)           person-years         Model 1 (HR [95%CI])         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 2 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0.74, 1.05)         0.97 (0.82, 1.14)	N = 4919, deaths = 875*	2199 / 445	1117 / 171	1603 / 259				
person-years         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 2 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0.74, 1.05)         0.97 (0.82, 1.14)	Crude incidence rate/1000	31.5 (28.7. 34.4)	23.4 (20.2, 27.2)	24.8 (22.0, 28.0)				
Model 1 (HR [95%CI])         1 [reference]         0.77 (0.65, 0.92)         0.82 (0.71, 0.96)           Model 2 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0.74, 1.05)         0.97 (0.82, 1.14)	person-vears		,,,	(, _0.0)				
Model 2 (HR [95%CI])         1 [reference]         0.87 (0.73, 1.04)         0.94 (0.80, 1.11)           Model 3 (HR [95%CI])         1 [reference]         0.88 (0.74, 1.05)         0.97 (0.82, 1.14)	Model 1 (HR [95%CII)	1 [reference]	0.77 (0.65 0.92)	0.82 (0.71 0.96)				
Model 3 (HR [95%CI]) 1 [reference] 0.88 (0.74 1.05) 0.97 (0.82 1.14)	Model 2 (HR [95%CII)	1 [reference]	0.87 (0.73, 1.04)	0.94 (0.80, 1.11)				
	Model 3 (HR [95%CII)	1 [reference]	0.88 (0.74, 1.05)	0.97 (0.82 1.14)				

Supplementary Table 11. Occupational physical activity and all-cause mortality and cardiovascular disease among adults with type 2 diabetes in employment

Model 4 (HR [95%CI])	1 [reference]	0.89 (0.74, 1.07)	0.97 (0.82, 1.14)

LTPA: leisure-time physical activity, MET: metabolic equivalent, HR: hazard ratio, sHR: subdistribution hazard ratio

\*Participants reporting any heavy manual work in UK Biobank. Combining 'manual work' and 'heavy manual work' in China Kadoorie Biobank.

Model 1: adjusted for sex and age (time-scale).

Model 2: Multivariable-adjusted,

UK Biobank: Model 1 + education (no qualifications, qualifications, not college/university degree, college/university degree), Townsend deprivation index (continuous), living with partner (yes/no), ethnicity (European, South Asian, African Caribbean, other), transportation (passive, walking, cycling, working from home), smoking (never, former, current), alcohol intake (never, former, current-<3 times/week, current->3 times/week), diet quality index (0, 1, 2-3), body mass index (continuous), family history of diabetes, cardiovascular disease, or cancer (yes/no), inclusion method (self-reported type 2 diabetes/use of medication or biochemistry), depression (yes/no), loneliness (yes/no), diabetes duration (continuous), leisure-time physical activity (continuous),

China Kadoorie Biobank: Model 1 + education (no school or primary school, middle school, High school or higher), household income (<10,000 yuan/y, 10,000-19,999 yuan/y, 20,000-34,999 yuan/y,  $\geq$ 35,000 yuan/y), marital status (married, yes/no), has health cover (yes/no), transportation (passive, walking, cycling, working from home), smoking (never, occasional, former regular, current), alcohol intake (never/occasionally, former weekly, current, <3 days/week, current  $\geq$ 3 days/week), regular fruit consumption ( $\geq$ 4 days/week, yes/no), regular meat consumption ( $\geq$ 4 days/week, yes/no), body mass index (continuous), family history of diabetes, cardiovascular disease, or cancer (yes/no), inclusion method (self-report or biochemistry), experienced food shortage with weight loss (yes/no), major depression in last 12 months (yes/no), diabetes duration (continuous), leisure-time physical activity (continuous)

Model 3: Model 2 + adjustment for body mass index

Model 4: Model 3 + adjustment for use of glucose-lowering drugs, statins, and blood-pressure-lowering drugs

- 1. Pearce M, Strain T, Kim Y, Sharp SJ, Westgate K, Wijndaele K, et al. Estimating physical activity from self-reported behaviours in large-scale population studies using network harmonisation: findings from UK Biobank and associations with disease outcomes. Int J Behav Nutr Phys Act. 2020;17(1):40.
- Bennett DA, Du H, Clarke R, Guo Y, Yang L, Bian Z, et al. Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women. JAMA Cardiol. 2017;2(12):1349-58.